Cardio Diagnostics Takes on $393B Heart Disease Crisis with AI

Heart disease remains the leading cause of death in the United States, with cardiovascular disease accounting for more than 940,000 deaths in 2022 alone, according to the American Heart Association (AHA). Into this persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics, and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw. The company's approach is distinct and gives it a defensible clinical position due to its ability to detect coronary heart disease earlier and with high sensitivity. This is critical given that annual health care costs for cardiovascular conditions are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. Cardio Diagnostics' recent commercial and regulatory milestones further shape the investment thesis, positioning the company to address a massive and growing market.

The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the disease. Cardio Diagnostics leverages AI and epigenetic biomarkers to identify coronary heart disease earlier than traditional methods, potentially transforming how cardiovascular risk is assessed. The company's technology could significantly reduce the burden of heart disease by enabling proactive, personalized interventions. As healthcare costs continue to rise, innovative solutions like Cardio Diagnostics' blood-based test could play a pivotal role in curbing expenses and improving patient outcomes. For more information, visit the company's newsroom at https://ibn.fm/CDIO and review the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.

Forward-looking statements in this article are subject to risks and uncertainties, including those detailed in the Company's SEC filings. Undue reliance should not be placed on these statements, and all parties undertake no duty to update this information unless required by law. Read more about Cardio Diagnostics' innovative approach at InvestorWire.